Application of antacid in treatment of lactic acidosis

Pegylated calcium carbonate mineralized nanoparticles (ARA) prepared by bionic mineralization method capture and neutralize lactic acid, solving the problem of hydrogen ions and lactic acid accumulation in lactic acid acidosis, achieving effective therapeutic effects and showing Good biocompatibility.

CN118987264APending Publication Date: 2024-11-22RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411048105.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art cannot effectively neutralize the accumulation of excessive hydrogen ions and lactic acid in lactic acid acidosis for a long time, resulting in limited therapeutic effects and side effects.

Method used

Using polyethylene glycolized calcium carbonate mineralized nanoparticles (ARA) prepared based on bionic mineralization method, nanoparticles formed by complexing polyethylene glycolized polyglutamic acid and calcium ions capture and neutralize lactic acid to form dilute solution Calcium lactate, reducing hydrogen ions and free lactic acid levels.

Benefits of technology

ARA effectively neutralizes hydrogen ions in the long-term circulation in the body, reduces lactate levels, significantly improves survival rate, and alleviates sepsis-related encephalopathy. It also has no inflammation or biochemical abnormal reactions in normal mice, showing good biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987264A_ABST
    Figure CN118987264A_ABST
Patent Text Reader

Abstract

The invention provides application of an antacid in treatment of lactic acidosis, and belongs to the technical field of biological medicine. The invention provides an application of PEGylated calcium carbonate mineralized nanoparticles as an antacid, and the PEGylated calcium carbonate mineralized nanoparticles are formed by complexing PEGylated polyglutamic acid and calcium ions and then mineralizing. The pegylated calcium carbonate mineralized nanoparticles can be well used as an antacid for treating lactic acidosis, especially an antacid for treating pyotoxic lactic acidosis. The antacid not only can neutralize hydrogen ions, but also can form diluted and dissolved calcium lactate, so that the level of free lactic acid is reduced, and lactic acid acidosis is relieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of an antacid in treating lactic acidosis. Background Art

[0002] Acidosis caused by increased blood lactate levels due to various reasons is called lactic acidosis. Lactic acidosis can occur in various diseases, such as sepsis, tissue hypoperfusion caused by hemorrhagic shock, diabetes, malignant tumors, liver and kidney failure, congenital mitochondrial diseases, etc., and is associated with poor prognosis and high mortality. There is currently a lack of effective treatment for lactic acidosis, and once it occurs, the mortality rate is extremely high.

[0003] At present, the clinical treatment of lactic acidosis is usually to use sodium bicarbonate injection to neutralize blood hydrogen ions. Although this method can temporarily restore blood pH, the main source of lactic acid production is activated immune cells, visceral and muscle tissues, or malignant tumor cells, which leads to continuous and persistent lactic acid accumulation. Sodium bicarbonate cannot be used in large quantities for a long time to prevent alkalosis. Therefore, sodium bicarbonate therapy cannot effectively neutralize the lactic acid that is constantly generated in the body. In addition, it also carries the risk of side effects such as bicarbonate overdose and sodium overdose.

[0004] Clinical studies have shown that there is very limited evidence for the effectiveness and safety of sodium bicarbonate therapy, as it does not improve survival or organ failure and may even potentially increase mortality. Until now, research on safe and effective drugs has been the focus of attention. Therefore, there is an urgent need to develop a new long-acting agent that can effectively neutralize excess lactic acid to relieve lactic acidosis.

[0005] Related studies have shown that lactic acidosis occurs due to metabolic disorders that lead to increased lactate production and lactate clearance, which in turn leads to lactate accumulation. For example, the development of sepsis is often accompanied by the occurrence of lactic acidosis. Sepsis is a serious disease associated with immune dysfunction, and 1 / 6 to 1 / 3 of sepsis patients may die. Lactic acidosis in patients has a high specificity for predicting sepsis mortality.

[0006] Studies have found that extracellular hydrogen ions can activate acid-sensing ion channels (ASICs), thereby affecting the immune system. For example, extracellular acidification (pH 6.0) can promote M1 polarization of bone marrow-derived macrophages (BMDMs). Extracellular acidification induces mitochondrial stress by activating ASIC1a, leading to inflammation. The acidic microenvironment in the synovial fluid of patients with rheumatoid arthritis can promote synovial inflammation. The acidic environment can also change the permeability of the blood-brain barrier (BBB), leading to further brain damage, which may also be a contributing factor to the development of sepsis-associated encephalopathy (SAE).

[0007] The increased mortality of SAE patients is closely related to the increase in lactate levels. Various polymer materials have been developed in the construction of acid-sensitive nanosystems. For example, in the cationic material PEG-b-PMNT, the hydrophobic benzylamine group can be protonated under acidic conditions, while amphiphilic materials such as polyethylene glycol-poly(methyl methacrylate-2-diisopropyl methacrylate) (PEG-PDPA) can bind excess hydrogen ions for drug release. However, lactic acidosis is caused by the accumulation of hydrogen ions and lactic acid (the ionized form of lactic acid), and hydrogen ions alone cannot fully alleviate lactic acidosis.

[0008] In the past, relatively few studies have examined the role of lactate ions in acidosis. Clinical studies have found that a decrease in plasma lactate concentration indicates a decrease in the predicted outcome of death. Extracellular lactate can also inhibit the movement of CD4+ and CD8+ T cells. In CD4 T helper cells, sodium lactate can induce the transformation of the Th17 subset. In addition, high concentrations of lactate ions can activate the MCT1 / NF-kB / COX-2 pathway, leading to upregulation of PD-L1 in neutrophils. It has been reported that upregulation of PD-L1 can delay neutrophil apoptosis. Delayed apoptosis leads to excessive accumulation of neutrophils in organs such as the lungs, resulting in immunosuppression, tissue damage, and ultimately death. The mechanism by which lactate causes lactic acidosis is still unclear. In addition, there is currently no effective and safe drug that can simultaneously address the accumulation of hydrogen ions and lactate to mitigate the adverse progression of lactic acidosis and related diseases.

[0009] Therefore, whether a long-acting antacid can be developed to specifically solve the problem of neutralizing excess hydrogen ions and reducing excess lactic acid accumulation has become a technical problem that needs to be urgently solved in the treatment of lactic acidosis. Summary of the invention

[0010] The present invention is to solve the above technical problems, thereby providing an application of an antacid in treating lactic acidosis. The technical purpose of the present invention is to provide a long-acting antacid that can effectively treat lactic acidosis by neutralizing excess hydrogen ions and reducing excess lactic acid accumulation.

[0011] In order to achieve the above technical objectives, the present invention proposes a nano acid reversal agent based on a biomimetic mineralization method, which is intended to synergistically achieve the neutralization of lactate hydrogen ions and the reduction of free lactate ions, and ultimately alleviate lactic acidosis. The inventors have found that the PEGylated calcium carbonate mineralized nanoparticles formed by mineralization after complexing PEGylated polyglutamic acid with calcium ions can be used as an antacid to achieve a new method for treating lactic acidosis. Therefore, the present invention provides a new application of PEGylated calcium carbonate mineralized nanoparticles as an antacid.

[0012] Furthermore, the application is to use the PEGylated calcium carbonate mineralized nanoparticles as an antacid for treating lactic acidosis.

[0013] Furthermore, the application is as an antacid for treating septic lactic acidosis.

[0014] Furthermore, the mineralization occurs under the promotion of sodium carbonate.

[0015] Furthermore, the dosage of the antacid is 1 to 2 mg / kg.

[0016] The above-mentioned antacid provided by the present invention is mainly through the complexation between PEGylated polyglutamic acid and calcium ions, and with the participation of carbonate ions, PEGylated calcium carbonate mineralized nanoparticles (named ARA) are produced. Experimental studies have found that during the long-term circulation process in the body, the ARA can capture the lactic acid continuously produced in tissues and organs, and convert it into dilute soluble calcium lactate, thereby neutralizing hydrogen ions and reducing the level of free ions in lactic acid. It is also found that ARA can inhibit the delayed apoptosis of human primary neutrophils induced by excessive lactic acid. In the sepsis-induced lactic acidosis mouse model, the blood lactate level of ARA-treated mice was maintained within the normal range, the level of inflammatory factors decreased, and the accumulation of organ neutrophils was significantly reduced, resulting in an increase in survival rate of about 50%, and septic encephalopathy was significantly weakened. In addition, ARA can be gradually degraded in normal mice without causing inflammation, abnormal biochemical markers or cognitive behavior, indicating that it has good biocompatibility. In addition, large animal experiments were carried out on the pig septic lactic acidosis model, and it was found that ARA can quickly reduce blood lactate levels to keep them within the normal range. At the same time, the levels of inflammatory factors in the blood and the accumulation of neutrophils in organs were reduced. In summary, the present invention confirms that the provided PEGylated calcium carbonate mineralized nanoparticles can be used as a new type of antacid or acid reversal agent for treating lactic acidosis.

[0017] The inventors found through research that excessive lactic acid can induce delayed neutrophil apoptosis, and inhibiting the monocarboxylate transporter MCT1 to inhibit the transport of lactic acid into cells can alleviate this phenomenon, which suggests the harmful mechanism caused by the accumulation of lactate ions. Based on this discovery, the present invention proposes the use of pegylated calcium carbonate mineralized nanoparticles (ARA) as a new type of antacid, which can capture lactic acid in the acidic environment of low perfusion organs. ARA can not only neutralize hydrogen ions, but also form dilute soluble calcium lactate, thereby reducing free lactic acid levels and alleviating lactic acidosis. Therefore, the present invention introduces a new class of acid reversal agents, which realizes an innovative strategy of simultaneously neutralizing lactic acid and reducing lactic acid levels in the treatment of lactic acidosis.

[0018] The beneficial effects of the present invention are as follows:

[0019] The present invention proposes an acid reversal agent (ARA) based on a biomimetic mineralization method, which mainly forms PEGylated calcium carbonate mineralized nanoparticles under the promotion of carbonate ions through the complexation between PEGylated polyglutamic acid and calcium ions. In the long-term circulation in the body, these drugs can capture lactic acid, form a small amount of soluble calcium lactate, and finally neutralize hydrogen ions and reduce the level of free lactic acid. Experiments have confirmed that ARA can inhibit the delayed apoptosis of neutrophils caused by lactic acid. In addition, after intravenous injection of ARA, the blood lactate level of mice with septic lactic acidosis remained normal, the level of inflammatory factors was significantly reduced, the accumulation of neutrophils in organs was reduced, the survival rate was significantly improved, and sepsis-related encephalopathy was alleviated. ARA can be gradually degraded in normal mice, does not cause inflammation, abnormal biochemical indicators, cognitive impairment, and has good biocompatibility. In addition, we studied septic lactic acidosis in pigs and found that intravenous injection of ARA can quickly maintain blood lactate levels within the normal range, reduce the level of inflammatory factors, and significantly reduce the accumulation of neutrophils in organs. Therefore, the present invention provides a novel method for treating lactic acidosis by simultaneously neutralizing lactate and reducing lactate levels. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of the ARA model for alleviating lactic acidosis.

[0021] Figure 2 The present invention found that lactate aggravates sepsis and inhibits neutrophil apoptosis; (A) Experimental flow chart: 30 minutes before inducing sepsis in CLP mice, 50 mg / kg of lactate channel MCT1 inhibitor AZD3965 or 0.5 g / kg lactate was intraperitoneally injected, and the daily survival rate of each group within seven days after surgery was recorded; (B) The survival rates of different groups were compared using the log-rank test, with n=30 in each group. CLP model mice injected with AZD3965 showed an increased survival rate, while the simultaneous injection of 0.5 g / kg lactate reduced their survival rate (Sham: this group of mice underwent abdominal surgery but no colon ligation and puncture); (C) Human neutrophils were extracted from the blood of healthy volunteers and cultured in vitro. After stimulation with 20 mM lactate or 50 mM sodium lactate, the cell survival rate was increased by CCK8 detection, and the addition of 5 μM AZD3965 alleviated the inhibitory effect of lactic acid / sodium lactate on neutrophil apoptosis (n=6, Ctrl: neutrophil control); (D) Representative images showing the protein levels of apoptosis-related genes analyzed by Western blot, the anti-apoptotic gene BCL-2 protein was upregulated, while the pro-apoptotic gene Bax protein was downregulated, and AZD3965 alleviated the effects of lactic acid and sodium lactate; *** P < 0.001, # P<0.05, ### P<0.001.

[0022] Figure 3 The synthesis principle and characterization of ARA; (A) The carboxyl group on PEG-PGlu complexes with calcium ions, and then sodium carbonate is added to promote the mineralization reaction to form PEGylated calcium carbonate mineralized nanoparticles (ARA); (B) DLS and TEM characterize the particle size and morphology of ARA; (C) The energy spectrum is used to characterize the elemental composition inside ARA, including elements such as Ca, O, and C; (D) Reaction of ARA with lactic acid: lactic acid is added to the nanoparticles to form calcium lactate, and the nanoparticle solution changes from white to colorless and transparent, and bubbles are generated; then, a calcium ion indicator (calcium carboxylate H2Ind) is added to the solution to make the solution dark red, indicating that calcium ions interact with Hind2- to form CaInd. After the EDTA solution is added, the calcium ions are replaced, turning the solution dark blue; (E) Principle of the reaction between lactic acid and ARA: lactic acid reacts with calcium carbonate nanoparticles to form calcium lactate, carbon dioxide, and water, resulting in the consumption of lactic acid.

[0023] Figure 4 TEM-EDS elemental analysis of ARA.

[0024] Figure 5 ARA can restore lactate-inhibited apoptosis of cultured neutrophils in vitro; (A) CCK8 assay showed that primary human neutrophils were stimulated by 20 mM lactate in the culture medium and their viability was enhanced; before adding an equal amount of lactate to the culture medium, they were reacted with excess ARA, and then the resulting product was introduced into the culture medium; compared with the lactate-stimulated group, neutrophil viability was reduced, and the addition of ARA alone did not affect cell viability (n=6, *** P < 0.001, ## P<0.01); (B) Representative images of Western blot analysis showed that lactate stimulation led to a decrease in the expression of the pro-apoptotic protein Bax and an increase in the expression of the anti-apoptotic protein Bcl-2, and ARA could inhibit the effect of lactate; (C) Overview of the mechanism of action: A sepsis (CLP) model was established to increase the lactate level in the blood of mice, which could lead to delayed neutrophil apoptosis. The lactate channel inhibitor AZD3965 could inhibit the entry of lactate into cells, and ARA could neutralize the lactate produced by tissues and organs. All these interventions could alleviate the problem of delayed neutrophil apoptosis induced by lactate. Figure 6 ARA can reduce the lactate level, organ damage and mortality of CLP mice; (A) 2 mg / kg ARA was injected 6 and 18 hours after CLP modeling, and ARA was observed for 24 hours to reduce the blood lactate level of CLP model mice to a level similar to that of the normal control group (n=6, ** P<0.01, ###P<0.001); (B) ARA reduced the levels of inflammatory factors IL-6 and TNF-α in CLP model mice 24 hours after surgery (n=6, *** P<0.01, ### P<0.001); (C) Immunohistochemical staining of the neutrophil marker MPO showed that ARA reduced the accumulation of neutrophils in the lungs of CLP mice, and there was almost no obvious neutrophil infiltration in the lung tissues; (D) F4 / 80 immunohistochemical staining showed that ARA alleviated the infiltration of macrophages in the lung tissues of CLP mice; (E) Injection of ARA significantly increased the survival rate of CLP model mice by about 2 times ( *** P<0.01, # P<0.05); (F) Schematic diagram: Behavioral tests were performed 1 week after CLP surgery, and the CLP mice were tested for cognitive impairment using the NOR test; (G) The NOR test showed that CLP mice showed cognitive impairment, and ARA could significantly rescue the cognitive impairment of CLP mice, while ARA itself had no effect on normal mice (n=5, *P<0.05, #P<0.05); (H) The Y-maze experiment showed that CLP mice had no spatial memory impairment, and ARA had no effect on normal mice. The left figure is a schematic diagram of the Y-maze; (I) Schematic diagram: CLP mice were tested for cognitive impairment using OFT; (J) There was no significant difference in the total distance of OFT among the mice in each group, indicating that CLP did not affect motor ability, and ARA alone had no effect on normal mice (n=5, **P<0.01, #P<0.05); (K) The time spent in the center of OFT showed that CLP mice showed obvious anxiety-like behavior, which could be rescued by ARA injection, while ARA alone had no effect on normal mice.

[0025] Figure 7 The role of ARA in alleviating organ damage in septic mice; (A) ARA alleviated macrophage infiltration in the liver of CLP mice (F4 / 80 immunohistochemical staining); (B) ARA alleviated macrophage infiltration in the kidney of CLP mice (F4 / 80 immunohistochemical staining); (C) ARA alleviated the activation of microglia in the brain of CLP mice (IBA1 immunohistochemical staining) (scale bar represents 0.1 mm).

[0026] Figure 8ARA showed good safety in normal mice; 8-week-old normal mice were intravenously injected with 2 mg / kg ARA. ICP-MS analysis of calcium content in (A) heart, (B) liver, (C) spleen, (D) lung, and (E) kidney 2 hours, 8 hours, 12 hours, 24 hours, 3 days, 7 days, 21 days, and 30 days after injection showed that calcium levels returned to normal in about 7 days (n=3, *P<0.05, **P<0.01, ns indicates no statistical significance); (F) ELISA detection showed that there was no significant change in the levels of inflammatory factors IL-6 and TNF-α in the plasma of normal mice 24 hours after injection of ARA (n=6, ns indicates no statistical significance); (G) MPO immunohistochemical staining showed that 2 mg / kg There was no accumulation of neutrophils in lung tissues within a week after ARA. (H) F4 / 80 immunohistochemical staining showed that ARA did not lead to the aggregation of macrophages. (I) Within 0 to 30 days, injection of ARA had no effect on the levels of two major electrolytes, sodium and chloride, in the blood. (J) Within 0 to 30 days, ARA had no effect on the plasma ALB / GLB ratio and (K) BUN (blood urea nitrogen).

[0027] Fig. 9 ARA cannot induce macrophage accumulation in septic mice; F4 / 80 immunohistochemical staining results show that injection of ARA in normal mice does not lead to accumulation of macrophages in (A) kidneys and (B) livers (scale bar shows 0.1 mm).

[0028] Fig.10 ARA can alleviate lactic acidosis in sepsis in pigs; (A) Experimental procedure: LPS was injected into the superior vena cava of pigs to simulate acute infection, and a rescue dose of 1 mg / kg of ARA was injected at the same time to establish a Bama miniature pig sepsis model. Plasma samples were collected at 2, 6, 12 and 24 hours, and the levels of lactate and inflammatory factors were determined by ELISA. The pigs were killed 24 hours later, and organ tissues were selected for MPO and F / 4 / 80 immunohistochemical staining; (B) Injection of ARA reduced the lactate level and maintained it at a level similar to that of the normal control group; (C) Enzyme-linked immunosorbent assay showed that ARA injection could reduce the levels of inflammatory factors IL-6 and (D) TNF-a in the blood of septic pigs; (E) Immunohistochemical staining results: 24-hour organ samples showed that the infiltration of neutrophils and (F) macrophages in the lungs of LPS-injected pigs was significantly reduced after ARA injection.

[0029] Fig.11 ARA injection also reduced the infiltration of neutrophils in the liver (A) and kidney (B). DETAILED DESCRIPTION

[0030] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is described in detail below in conjunction with the embodiments. It is necessary to point out that the following embodiments are only used to explain and illustrate the present invention and are not used to limit the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the above invention content still belong to the protection scope of the present invention.

[0031] Example 1

[0032] I. Experimental methods (I) Study on the effect of lactic acid on aggravating sepsis and delaying neutrophil apoptosis

[0033] The cecal ligation and puncture method (CLP) was used to establish a septic mouse model, and to study whether the increase in lactate would further reduce the survival rate of septic mice, and whether inhibiting the function of the lactate transport channel MCT1 could improve the survival rate of septic mice (see the schematic diagram of the mechanism). Figure 1 ).

[0034] Lactic acid (0.5 g / kg) or lactate channel MCT1 inhibitor AZD3965 (50 mg / kg) were intraperitoneally injected 30 minutes before modeling. Seven days after surgery, the daily survival rate of each group was recorded ( Figure 2 It was observed that the survival rate of the CLP model increased significantly (by about 50%) after administration of AZD3965, while lactate further decreased the survival rate of CLP mice, consistent with clinical studies ( Figure 2 Middle B). Delayed neutrophil apoptosis in sepsis leads to organ dysfunction and even death.

[0035] In order to verify whether the increase of lactate or lactate ions would delay the apoptosis of neutrophils, we extracted blood from healthy volunteers and cultured neutrophils in vitro. The results showed that after stimulation with 20mM lactate or 50mM sodium lactate, the activity of neutrophils was significantly higher than that of the control group ( Figure 2 Middle C). The expression of anti-apoptotic protein BCL-2 is upregulated, while the expression of pro-apoptotic protein Bax is downregulated ( Figure 2 MCT1 allows lactate to enter neutrophils, and we found that AZD3965 (5 μM) restored the regulatory effects of lactate or sodium lactate on apoptosis-related proteins in neutrophils ( Figure 2 C and D). Thus, lactate reduces survival in patients with sepsis and leads to delayed neutrophil apoptosis.

[0036] (II) Preparation and characterization of ARA

[0037] (1) The synthesis method of methoxy-polyethylene glycol-poly sodium L-glutamate (mPEG-P(Glu)) polymer is as follows: First, 1 ml Tris-HCl buffer (10 mM, pH 7.6) containing 10 mg CaCl2 and 10 mg mPEG-P(Glu) polymer. Then, 10 mg Na2CO3 and 1 mL HEPES (50 mM, pH 7.1, NaCl 140 mM) were slowly dripped into the mixture. The mixture was stirred at 4 °C for 4 h, then centrifuged (14000 rpm, 15 min) to remove excess ions and copolymers, and resuspended in saline to obtain PEGylated calcium carbonate mineralized nanoparticles (Ca2CO3-NPs, named ARA).

[0038] The particle size distribution of ARA was characterized by DLS (ZetasizerNano S, Malvern, UK), and its morphology and elemental composition were observed by transmission electron microscopy (TEM, TALOS F200X).

[0039] (III) Calcium lactate detection

[0040] First, 0.9306 g EDTA-2Na was completely dissolved in 50 mL ddH2O to prepare a 0.05 M EDTA solution. Then, 90 μL of 200 mg / ml lactic acid solution was dropped into 0.2 ml of 50 mg / ml CaCO3-NPs solution to obtain a calcium lactate solution.

[0041] Next, transfer the calcium lactate solution to a 100ml beaker and add 25ml ddH2O. Then, 1ml MgSO4 (5mg / mL), 2ml 5M NaOH, 1ml 2.4M HCl and 10mg calcium carboxylate indicator (No.C104974, Aladdin). The mixed solution should appear dark red. Then, under stirring, drop 0.05M EDTA solution into the mixture and observe the color change of the solution. Take pictures with a camera.

[0042] (IV) Animal sepsis model

[0043] (1) Cecal ligation and puncture (CLP) mouse model

[0044] The experimental animal protocol was approved by the Standing Committee of the Tongji University Animal Committee, and mice were housed in the Tongji University Experimental Animal Center in accordance with federal guidelines (experimental number: TJTJ01223102). Mice were anesthetized with isoflurane during surgery, and after laparotomy, the cecum was ligated with a 4.0 thread and punctured with a 21g needle. The cecum was then placed into the abdominal cavity, the wound was sutured, and analgesics were applied to the wound. Immediately after surgery, mice were resuscitated with subcutaneous injection of normal saline (5mL / 100g) and water loss was replenished. Sham mice underwent the same surgical procedure, but without ligation and puncture.

[0045] In order to detect the effect of lactate or MCT1 inhibitor on survival rate, 0.5g / kg lactate or 50mg / kg lactate channel MCT1 inhibitor AZD3965 was injected intraperitoneally immediately after the CLP mouse model was established. In addition, 2mg / kg ARA was injected intravenously into CLP mice 6 and 18 hours after surgery to detect the effect of ARA or PBS. 24 hours after surgery, the mice were anesthetized with sodium pentobarbital to collect blood and organs. In different experimental groups, some mice were taken to continue feeding and the survival rate within 7 days after surgery was observed.

[0046] Survival rate study: Different treatments were given after surgery, 30 rats in each group, followed up for 7 days, and the survival rate was observed.

[0047] (2) Study on LPS injection in Bama miniature piglets

[0048] The experimental animal protocol was approved by the Standing Committee of the Animal Committee of the Experimental Animal Center of the Agricultural Experimental Field of Shanghai Jiao Tong University. The Experimental Animal Center raises pigs according to federal guidelines (No. 20230404). Based on the previous study on the construction of the LPS injection model, we injected LPS into 4-week-old male Bama miniature piglets. Briefly, the compound anesthetics of thiophene hydrochloride and zolazepam hydrochloride for injection (VIRBAC, France), which do not cause respiratory depression and have sedative, analgesic and anesthetic effects, were used for piglet anesthesia. 0.25 mg / kg LPS was intravenously dripped into the superior vena cava within 30 minutes. The control group was injected with an equal amount of normal saline. 1 mg / kg ARA was intravenously dripped simultaneously with LPS. Venous blood was collected at 2, 6, 12, and 24 h after injection, and plasma was taken to detect lactate levels and inflammatory factors IL-6 and TNF-α levels.

[0049] (V) Preparation and treatment of human peripheral blood neutrophils

[0050] The collection of human neutrophils and related experimental protocols were approved by the Institutional Research Ethics Committee of Shanghai Fourth People's Hospital (No.: 2023073-001). 20 ml of blood was collected from healthy volunteers using heparinized tubes. Circulating neutrophils were separated by 3% dextran precipitation (Sigma, USA). The cells were then centrifuged through discontinuous Ficoll (GE Healthcare, UK). Neutrophils were lysed at 10 6 The concentration of 100 / ml was suspended in DMEM containing 10% FBS (Invitrogen, CARAda) and 1% penicillin-streptomycin (Invitrogen). 20mmol / L lactic acid (Sangon, China), 20mmol / L sodium lactate (Sodium lactate, China) or 5μmol / LA ZD3965 (MedChemExpress, China) were added to the neutrophil culture medium of each group. The product of the reaction of lactic acid and excessive ARA was added to the culture medium.

[0051] (VI) Cell counting kit-8 (CCK-8) to measure cell viability

[0052] To detect the viability of human neutrophils in different experimental groups, CCK-8 assay was performed according to the instructions of Cell Counting Kit-8 (MedChemExpress, China).

[0053] (VII) Western blot analysis

[0054] Neutrophil proteins were collected using protein lysis buffer (M-PER mammalian protein extraction reagent, Thermo, USA) and protease inhibitor cocktail (Bimake, Shanghai, China, dilution: 1:100). After SDS-PAGE electrophoresis, the proteins were transferred to polyvinylidene fluoride (PVDF) membranes. After blocking with 3% BSA, the membranes were incubated with primary antibodies as follows: Bcl-2 antibody (Cell Signaling Technology, USA, #2876, dilution 1:1000), Bax antibody (Cell Signaling Technology, USA, #2772, dilution 1:1000), β-Actin (Cell Signaling Technology, USA, #3700, dilution 1:2000). The secondary antibodies were: anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology, USA, 7074S, 1:3000 dilution) and anti-mouse IgG HRP-linked antibody (Cell Signaling Technology, USA, 7076S, 1:3000 dilution).

[0055] (VIII) Inductively coupled plasma mass spectrometry (ICP-MS)

[0056] After taking the mouse organs after different treatment times, the organs were accurately weighed and entrusted to Hangzhou Yanqu Information Technology Co., Ltd. for ICP-MS analysis.

[0057] (1) Detection of blood lactate and inflammatory factor levels

[0058] Blood was collected into a tube containing heparin and centrifuged to obtain the supernatant plasma. Lactate levels were detected using the L-Lactate Assay kit (colorimetric method) (Abcam, USA, ab65331). Elisa detection kits for mouse IL-6 (Quantikine Elisa SixPak, R&D, SM6000B) and TNF-α (Quantikine Elisa SixPak, R&D, SMTA00B) were used to detect mouse IL-6 and TNF-α levels. Enzyme-linked immunosorbent assay kits for porcine IL-6 (Abcam, ab100755) and TNF-α (Abcam, ab100756) were used to detect IL-6 and TNF-α levels in Bama miniature piglet blood.

[0059] (2) Field Test (OFT)

[0060] According to our previous study as a reference, each mouse was placed in the center of the open-air arena, and the movement of the mouse was recorded over a 10-min period using ANY-maze software (Stoelting, USA).

[0061] (3) New Object Recognition (NOR) Test

[0062] We performed the NOR test for testing learning and memory based on our previous study as a reference. The arena was used only once by a mouse. During the habituation process, the mouse was placed in the arena to explore for 10 min. Afterwards, two objects of similar size but different shapes and colors were placed in opposite corners of the arena. Then, the test mouse was placed in the center and allowed to explore for 10 min. After 24 h, one of the objects was changed and the mouse was allowed to explore again. The movement of the mouse was then recorded using the ANY-maze (Stoelting) method.

[0063] (4) Y-maze test

[0064] Each mouse was placed at the end of an arm and allowed to freely explore the arm for 5 min. The percentage of "correct" spontaneous changes was calculated. The movement of the mice was recorded using ANY-maze (Stoelting).

[0065] 2. Experimental Results

[0066] 1. Synthesis principle and characterization of ARA

[0067] The synthesis process of ARA is to complex the carboxyl group on mPEG-PGlu with calcium ions, and then add sodium carbonate to induce mineralization to obtain PEGylated ARA ( Figure 3 The particle size and morphology of ARA were characterized by DLS and TEM ( Figure 3 The elemental composition of ARA was determined using the energy spectrum, including calcium (Ca), oxygen (O), and carbon (C). Figure 3 C). Elemental analysis of ARA using TEM-EDS ( Figure 4 ).

[0068] In addition, after lactic acid was added to ARA, the white nanosphere solution became colorless and transparent, and bubbles were generated. Although calcium lactate is less soluble than sodium lactate, it still has a certain solubility. Because calcium lactate is less soluble, that is, it has a certain solubility, calcium ions should be detected in the solution. In order to confirm the presence of calcium ions in the solution after the reaction of ARA with lactic acid, a calcium ion indicator (calcium carboxylate H2Ind) was added to make ARA appear dark red. This indicates that the calcium ions in calcium lactate reacted with Hind2- to form CaInd. Subsequently, the addition of EDTA solution caused the displacement of calcium ions, turning the solution dark blue ( Figure 3In summary, lactic acid can react with calcium carbonate nanospheres to produce calcium lactate, carbon dioxide and water ( Figure 3 These results confirmed the successful synthesis of ARA.

[0069] 2. ARA has an inhibitory effect on delayed neutrophil apoptosis induced by lactate

[0070] Through in vitro culture of primary human neutrophils from healthy volunteers, it was observed that after adding lactic acid (20mM) to the cell culture medium for 24 hours, the activity of neutrophils was higher than that of control cells ( Figure 5 A), indicating delayed apoptosis. Despite the addition of lactate, the effective buffering capacity of the cell culture medium prevented significant changes in pH, suggesting that delayed apoptosis of neutrophils may be related to the increase in lactate ions.

[0071] We then evaluated the ability of ARA to counteract the effects of lactate. Before adding an equal amount of lactate to the culture medium, it was pre-reacted with an excess of ARA, and the resulting product was then added to the culture medium. Compared with the lactate-stimulated group, neutrophil viability was reduced ( Figure 5 ARA alone did not affect cell viability ( Figure 5 (A). The addition of lactate resulted in upregulation of the anti-apoptotic protein BCL-2 and downregulation of the pro-apoptotic protein Bax in neutrophils. However, the products produced by the reaction of ARA with lactate alleviated the increase in BCL-2 and decrease in Bax caused by lactate alone ( Figure 5 In addition, ARA alleviates the delayed apoptosis of neutrophils induced by lactate by reacting with lactate ( Figure 5 (C) These results suggest that ARA, a potent acid reversal agent, can inhibit delayed apoptosis of neutrophils in response to lactate.

[0072] 3. ARA can alleviate the symptoms of lactic acidosis and sepsis in mice

[0073] After the CLP mouse model was established, ARA was injected into the tail vein at a dose of 2 mg / kg at 6 and 18 hours after the model was established. At 24 hours, the blood lactate level of CLP mice was significantly higher than that of normal control mice. However, after the injection of ARA in the CLP group, the blood lactate level did not change significantly and was comparable to that of the normal control group ( Figure 6 ARA injection also resulted in a significant decrease in the levels of inflammatory factors IL-6 and TNF-a detected at 24 hours ( Figure 6 (B). Neutrophil accumulation in the lungs is a key factor in sepsis-induced lung injury. MPO immunohistochemical staining showed a significant decrease in the number of neutrophils in the lung tissue of CLP mice after ARA injection. This decrease was almost equivalent to the level observed in normal mice, and there was no obvious neutrophil infiltration in the lung tissue ( Figure 6In addition, the macrophage infiltration (F4 / 80 immunohistochemistry) in the ARA injection group was also significantly reduced ( Figure 6 D). It was further found that after ARA injection, the liver of CLP mice ( Figure 7 Middle A) and kidney ( Figure 7 The infiltration of macrophages (F4 / 80 staining) in the CLP model mice was also weakened after ARA injection. Figure 6 Middle E).

[0074] Sepsis-associated encephalopathy (SAE) is a serious complication of sepsis, which seriously affects the quality of life of patients and brings a heavy burden to their families and society. Behavioral tests were performed on surviving CLP mice in each group one week after surgery. First, the novel object recognition (NOR) experiment ( Figure 6 F), we found that CLP mice had learning and memory impairments that could be restored by injection of ARA. ARA itself did not impair the learning and memory of normal mice ( Figure 6 Middle G). In the Y-maze test, CLP mice did not show obvious spatial memory impairment. ARA also did not impair spatial memory ( Figure 6 In the open field test (OFT) ( Figure 6 In Figure 1), CLP mice spent less time in the central zone and showed anxiety-like behavior, which could be rescued by ARA. ARA itself did not induce anxiety-like behavior ( Figure 6 Middle J), ​​the open-field experiment showed that there was no significant difference in the total walking distance of each group of mice, indicating that CLP had no effect on motor skills, and injection of ARA had no effect on the motor skills of normal mice ( Figure 6 It has been reported that the hyperactivation of SAE48-associated microglia (IBA1 immunohistochemistry) in the brains of CLP mice was also alleviated by ARA ( Figure 7 Middle C).

[0075] Using mouse models, these findings validate the therapeutic role of ARA in reducing the manifestations and characteristics of septic lactic acidosis.

[0076] 4. ARA shows excellent safety

[0077] Eight-week-old normal male mice were randomly divided into a control group and a single intravenous injection of ARA (2 mg / kg). Figure 8 Middle A), liver ( Figure 8 Middle B), spleen ( Figure 8 Middle C), lungs ( Figure 8 Middle D) and kidney ( Figure 8ICP-MS calcium content analysis was performed at 2h, 8h, 12h, 24h, 3 days, 7 days, 21 days and 30 days after injection. The calcium content of the organs increased significantly after injection, but returned to normal levels around 7 days. 24 hours after injection, the levels of inflammatory factors IL-6 and TNF-α in each organ remained unchanged, and there was no inflammatory response ( Figure 8 Middle F). Throughout the week after injection, neutrophils in lung tissue ( Figure 8 Middle G) and macrophages ( Figure 8 In addition, in the kidney ( Fig. 9 Middle A) and liver ( Fig. 9 No macrophage accumulation was observed in B). The main ions (sodium and chloride) in the blood (0-30 days after ARA injection) ( Figure 8 I), serum albumin / globulin (ALB / GLB) ( Figure 8 Middle J), ​​blood urea nitrogen (BUN) level reflecting renal function ( Figure 8 These findings suggest that ARA has good safety and will not cause significant side effects on the body.

[0078] 5. ARA can reduce lactic acidosis in pig sepsis

[0079] The sepsis pig model was established by intravenous injection of 0.25 mg / kg lipopolysaccharide (LPS) in Bama miniature piglets. At the same time, we gave 1 mg / kg ARA as a rescue intervention. Blood samples were collected at 2, 6, 12, and 24 hours to measure lactate and inflammatory factor levels. The pigs were killed at 24 hours. Tissue samples were taken for immunostaining to detect the infiltration of neutrophils and macrophages in various organs ( Fig.10 Middle A). Blood lactate levels increased significantly 2 hours after LPS injection. ARA injection suppressed the increase in blood lactate levels and maintained them at a level similar to that of the healthy control group at 6 hours, whereas in the group that received LPS injection alone, levels peaked at 6 hours ( Fig.10 (middle B).

[0080] In addition, ARA significantly reduced the level of inflammatory factor IL-6 ( Fig.10 C) and TNF-α( Fig.10 ARA injection also significantly reduced the level of neutrophils in lung tissue ( Fig.10 Middle E) and macrophages ( Fig.10 F) infiltration, reducing the liver ( Fig.11 Middle A) and kidney ( Fig.11These results suggest that ARA exhibits a positive effect in large animals, reducing lactate and inflammatory factor levels and the accumulation of neutrophils and macrophages in various organs.

[0081] Conclusion

[0082] Lactic acidosis can lead to poor prognosis and high mortality in various related diseases. However, there is currently no safe and effective clinical treatment, which has focused attention on the development of new therapeutic agents.

[0083] When using sodium bicarbonate, the required dose needs to be accurately calculated and adjusted according to the results of blood gas analysis, especially the base excess (be) value. It should not be injected intravenously in large quantities in a short period of time. More importantly, sodium bicarbonate can only temporarily adjust the blood pH value according to the current blood gas data and cannot be administered for a long time to continuously neutralize lactic acid produced by poorly perfused organ tissues and other sources. In this study, the injection of 2 mg / kg ARA only at 6 and 18 hours after surgery can maintain the blood lactate level of CLP model mice at normal levels for 24 hours. In the acute sepsis pig model, a single injection of 1 mg / kg ARA can keep the blood lactate level consistent with the normal group, indicating that the convenience and effectiveness of ARA use far exceeds that of sodium bicarbonate. In conclusion, our study solves the clinically important problem of lactic acidosis and introduces and demonstrates that ARA is a potential, safer and more effective new drug for the treatment of lactic acidosis.

[0084] We found that excessive lactate ions can cause delayed apoptosis of human neutrophils, which is one of the reasons for the high mortality rate of sepsis. Therefore, based on the biomimetic mineralization method, we designed and synthesized nano ARA. During long-term circulation in the body, it can capture lactic acid to form dilute soluble calcium lactate, effectively neutralize the hydrogen ions in lactic acid, and reduce the level of free lactic acid. ARA has good biocompatibility and has shown significant therapeutic effects in the treatment of septic lactic acidosis in both large and small animal experiments. In summary, the present invention introduces a safe and effective antacid for the first time for the future clinical treatment of lactic acidosis.

Claims

1. A use of PEGylated calcium carbonate mineralized nanoparticles as an antacid, characterized in that: The PEGylated calcium carbonate mineralized nanoparticles are formed by mineralization after PEGylated polyglutamic acid is complexed with calcium ions.

2. The use according to claim 1, characterized in that: The application is to use PEGylated calcium carbonate mineralized nanoparticles as antacids for treating lactic acidosis.

3. The use according to claim 2, characterized in that: The application is as an antacid for treating septic lactic acidosis.

4. The use according to any one of claims 1 to 3, characterized in that: The mineralization is promoted by sodium carbonate.

5. The use according to any one of claims 1 to 3, characterized in that: The dosage of the antacid is 1-2 mg / kg.